Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports and paid a fee for this company profile page.
Please refer to the important disclosures below for additional details.
Rocket Doctor AI reaches SOC 2 Type I compliance, strengthening its enterprise position as the digital health market expands rapidly with rising AI adoption.
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) said its wholly owned Rocket Doctor platform achieved SOC 2 Type I compliance following an independent third-party audit of its security, privacy, and operational controls.
Rocket Doctor AI Inc.'s (AIDR:CSE; TREIF:OTC; 939:FRA) Clinical Decision Support System is being deployed in Alberta, Canada, on a small scale for a trial period with the goal of expanding it province-wide next year. This company's stock is rated Speculative Buy; read on to learn why.
Treatment.com AI Inc. has rebranded and reincorporated as Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) to reflect the integration of its proprietary AI-driven Global Library of Medicine (GLM) with the recently acquired Rocket Doctor Inc. Read why one analyst calls part of the company's offerings "Shopify for physicians."
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launches virtual screening for older adults in NYC, backed by US$1M from CVS Health Foundation, as it scales AI tools and patient reach. Read more about how this initiative is helping expand access to care and driving growth in virtual health innovation.
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launched its enhanced medical education suite in Minnesota, showing strong reliability and providing schools with up to 40% cost savings. Read on to find out how AI-simulated patients are reshaping medical education and enhancing clinical skills at scale.
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) subsidiary Rocket Doctor was chosen by the Larta Institute to participate in its Bioscience and Healthcare Accelerator program. Read on to learn why one analyst says it is time to buy this company's stock.
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) virtual care subsidiary, Rocket Doctor, has expanded its core virtual care services into New York and California. Separately, its virtual ER program, designed to reduce unnecessary emergency room visits, continues to demonstrate a strong impact. Over a 12-month period between 2023 and 2024, Rocket Doctor reported an 88% year-over-year increase in revenue."
Technical Analyst Clive Maund explains why he thinks now is an excellent time to buy or add to positions in Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA).
Rocket Doctor, under Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA), is now an in-network provider for New York Medicaid, expanding virtual healthcare access to 6.9 million beneficiaries. Find out how this milestone offers the possibility to reshape healthcare accessibility.
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has announced the release of its newly updated Medical Education Suite (MES). Read more to find out how this update is set to transform medical education and enhance training efficiency.
Healthcare artificial intelligence (AI) company Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has closed a non-brokered private placement for aggregate gross proceeds of CA$1.95 million. Find out why one analyst says the stock is a Strong Buy and worth going overweight on.
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on.
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has formally entered a collaborative agreement with UK-based AI healthcare technology company SPRYT Limited. Read how this partnership aims to change the way patients interact with their healthcare providers.
The parties intend to develop artificial intelligence-backed solutions to a problem in healthcare, for expanded use throughout and beyond the United Kingdom. Find out why one analyst is bullish on this company and its proprietary platform.
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced it will roll out a new AI (artificial intelligence) Pharmacy Assistant to support pharmacists. One analyst says the company has positioned itself as a "central go-to resource."
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has successfully seen the exercise of nearly 800,000 warrants issued on conversion of special warrants in June for gross proceeds of about CA$500,000. See why one technical analyst rates this stock a Buy as the company solidifies its investor confidence.
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has provided a general corporate update, detailing significant progress made through Q1 and Q2 of 2024. Read about what this means for the future of its platform, the Global Library of Medicine (GLM) and future projects.
Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher.
Treatment.com AI Inc. has entered into a collaborative agreement with Health Care Services International Inc. to leverage its advanced healthcare AI engine and enhance services. Read on to learn what this means for the growing sector.
Treatment.com AI Inc., a leader in artificial intelligence for healthcare education, has introduced two new tools for its Medical Education Suite (MES).
Canadian artificial intelligence (AI) and machine learning healthcare company Treatment.com AI Inc. is using AI to positively disrupt the healthcare sector. Canada is planning to fund the industry in a big way.
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock.
Canadian artificial intelligence (AI) and machine learning healthcare firm Treatment.com AI is breaking into the global healthcare AI market predicted to be worth US$187 billion by the end of the decade.
7/14/2026 – Rocket Doctor Achieves SOC 2 Type I Compliance, Reinforcing Trust, Security and Enterprise Readiness
6/30/2026 – Rocket Doctor Enters into a Primary Care Value-Based Care Agreement in the United States, Expanding In-Network Coverage by More Than 5 Million Members
6/23/2026 – Rocket Doctor Partners with Mindstride to Expand Access to After-Hours Healthcare Across Ontario, Alberta and British Columbia
6/23/2026 – Rocket Doctor Partners with Mindstride to Expand Access to After-Hours Healthcare Across Ontario, Alberta and British Columbia
6/18/2026 – Rocket Doctor Takes Center Stage in Inaugural NASCAR Cup Series Race at Naval Base Coronado as Primary Partner of Rick Ware Racing
6/18/2026 – Rocket Doctor Takes Center Stage in Inaugural NASCAR Cup Series Race at Naval Base Coronado as Primary Partner of Rick Ware Racing
6/16/2026 – Rocket Doctor AI Subsidiary Treatment.com Secures Year 2 NIH Funding to Advance AI-Powered Family Health History Tool
6/8/2026 – Rocket Doctor AI Launches a Strategic Marketing Partnership with Rick Ware Racing and FINTEKK AP for the 2026 NASCAR Cup Series, NHRA (National Hot Rod Association), World Supercross Championship, AFT (AMA - American Flat Track) and other Nati
6/2/2026 – Rocket Doctor AI Announces Strong Q1 Momentum Driven by U.S. Expansion, New Payer Contracts and Platform Growth
5/27/2026 – Rocket Doctor AI Announces Global Company Town Hall to Showcase 2025 Milestones; Q1 2026 Milestones and Strategic Vision
5/19/2026 – Rocket Doctor Enters into North Star Agreement
5/12/2026 – Rocket Doctor and University of Toronto Launch Digital Health Observership Program for Physician Assistant Students
5/4/2026 – Rocket Doctor AI Reports Strong 2025 Results, Validating Physician-Led Model with Key U.S. Payer Contracts and AI Innovation
4/29/2026 – Rocket Doctor Inc. Selected to Join Canadian Life Sciences Trade Mission to New York and New Jersey
4/21/2026 – Rocket Doctor Further Expands Maryland Access by ~ 250,000 Additional Members Through New In-Network Agreement
Important Disclosures
Rocket Doctor AI Inc. is a Billboard advertiser of Streetwise Reports and pays a flat fee. Fees fund both sponsor-specific activities and general report activities. Sponsor-specific activities may include aggregating content and publishing that content on the Streetwise Reports site, creating and maintaining company landing pages, interviewing key management, posting a banner/billboard, and/or issuing press releases.
The fees also cover the costs for Streetwise Reports to publish and syndicate investment opinion and comments, and also to curate or create sector-specific content.
Billboard advertising monthly fees range from $3,000 to $5,000.
This landing page contains a summary of the company that was prepared by that company.
Some landing pages contain investing highlights and a catalyst calendar that are prepared by that company.
The Expert Comments and Experts Following This Company sections of the landing page are compiled by Streetwise Reports.
There may be other information about the company that is not placed on the landing page, and Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on the landing page.
Readers should conduct their own research for all information publicly available concerning the company.
This landing page may be considered advertising for the purposes of 18 U.S.C. 1734.
Restructures
A stock restructure (or capital restructure) in the context of stocks generally refers to a broader set of corporate actions that change a company's capital structure–the mix of debt and equity, or the way shares are organized and distributed. This can include changes to the number of shares outstanding, share classes, or ownership proportions.
Technical Analyst Stewart Thomson explains why he likes Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA).
Streetwise Company Fact Sheet
